Holding types
Countries
Sectors
Analyst ratings
Market Data
Dividend
Live webcast will provide an update on the Company's upcoming catalysts, commercial strategy, facility operations and financing discussions as attention turns towards the road to FID Live webcast will provide an update on the Company's upcoming catalysts, commercial strategy, facility operations and financing discussions as attention turns towards the road to FID
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, today announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting on June 2, 2024 in Chicago, Illinois. Details of the presentation are as follows: Abstract.
FAQ
- What is FID ETF?
- Does FID pay dividends?
- What stocks are in FID ETF?
- What is the current assets under management for FID?
- What is FID average volume?
- What is FID expense ratio?
- What is FID inception date?